Free Trial
OTCMKTS:BVNRY

Bavarian Nordic 8/22/2024 Earnings Report

Bavarian Nordic logo
$12.19 +1.99 (+19.51%)
As of 11:41 AM Eastern

Bavarian Nordic EPS Results

Actual EPS
$0.16
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Bavarian Nordic Revenue Results

Actual Revenue
$205.99 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Bavarian Nordic Announcement Details

Quarter
Time
N/A
Conference Call Date
N/A
Conference Call Time
N/A

Upcoming Earnings

Bavarian Nordic's next earnings date is estimated for Thursday, August 28, 2025, based on past reporting schedules.

Conference Call Resources

Bavarian Nordic Earnings Headlines

Bavarian Nordic climbs after buyout offer
Genesis 14:13-17 [HIDDEN MEANING?]
A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthright” — a $150 trillion wealth vault that’s remained untouched for over a century. Jim Rickards believes President Trump is about to unleash it — and investors who move first could come out on top. The full story is now available.
See More Bavarian Nordic Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Bavarian Nordic? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Bavarian Nordic and other key companies, straight to your email.

About Bavarian Nordic

Bavarian Nordic (OTCMKTS:BVNRY) A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase III clinical trial for the treatment of SARS-CoV-2. The company has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. It operates in the United States, Canada, France, Germany, Spain, Australia, Switzerland, Sweden, Chile, Taiwan, the United Kingdom, Hong Kong, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.

View Bavarian Nordic Profile

More Earnings Resources from MarketBeat